TwoToBiotech's researchers have identified a novel human peptide hormone (P3) thatis expressed in activated immune cells.

The company subsequently developed a platform technology with several specific monoclonal antibodies against P3 in order to treat autoimmune diseases.In-vivo studies show that the antibody may be effectivefor treatment of type 1 and type 2 diabetes.TwoToBiotech is developing another novel human peptide hormone, APC1, for treatment of type 2 diabetes.

Initial tests on mice have shown promise.

The company has also isolated a novel human cardiac peptide that may have the potential tostrongly regulate glucose metabolism.